Clinical trials: Metabolism
Urea Cycle Disorder
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
This is an open-label study consisting of a transition period to RAVICTI, followed by a safety extension period for at least 6 months and up to 24 months of treatment with RAVICTI, depending on age at enrollment.
- Trial name
- NCT02246218
- Testing
- RAVICTI
- Where
- 17 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Amgen
Type II Diabetes Mellitus, Dyslipidemia
Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.
- Trial name
- NCT00344370
- Testing
- Pitavastatin, Atorvastatin
- Where
- 35 sites in Denmark, Germany and 4 more
- Volunteers
- 214 people
- Sponsor
- Kowa Research Europe
Obesity
Investigation of a New Diet for the Treatment of Obesity in the NHS
Over one in four adults living in the UK is living with obesity. Obesity is associated with health complications including type 2 diabetes, heart disease and depression.
- Trial name
- NCT05249439
- Testing
- I-SatPro weight loss programme, Tier 3 weight loss programme
- Volunteers
- 21 people
- Sponsor
- Imperial College London
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic…
- Trial name
- NCT01167881
- Testing
- BI 10773, Glimepiride
- Where
- 182 sites in United States, Argentina and 21 more
- Volunteers
- 1,549 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine.
- Trial name
- AWARD-9 (NCT02152371)
- Testing
- Dulaglutide, Insulin Glargine, Metformin
- Where
- 40 sites in United States, Czechia and 5 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
The purpose of this study is: To identify the common factor for L5 prevalence in patients with Metabolic Syndrome. To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- promoting factor and reduce L5 in…
- Trial name
- Merck-123 (NCT00988364)
- Testing
- Simvastatin, Vytorin, Ezetimibe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
Diabetes Mellitus, Type 2
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
- Trial name
- NCT00082381
- Testing
- Exenatide (AC2993), Insulin glargine
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 551 people
- Sponsor
- AstraZeneca
Mucopolysaccharidosis I, Hurler Syndrome
Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease
This is a multi-center, open label, study conducted to evaluate the safety of laronidase administered by intravenous drip infusion in Japanese patients with MPS I disease.
- Conditions
- Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
- Trial name
- NCT00258011
- Testing
- Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- Where
- 2 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Genzyme, a Sanofi Company
Diabetes, Depression
INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study
To provide better care and preventive services for people with both depression and diabetes, the investigators propose to develop and test whether interventions to reduce depressive symptoms can be integrated into routine…
- Conditions
- Diabetes, Depression, Cardiovascular Risk Factor
- Trial name
- INDEPENDENT (NCT02022111)
- Testing
- Patient Education and Behavioral Activation, Supporting Self-Care (care coordinators), Psychiatrist and Diabetologist Reviews
- Where
- 4 sites in India
- Volunteers
- 404 people
- Sponsor
- Emory University
Non Malignant Disorders, Immunodeficiencies
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients < 21…
- Conditions
- Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies
- Trial name
- NCT00744692
- Testing
- Unrelated Umbilical Cord Blood Transplant, Reduced Intensity Conditioning
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Duke University
Osteomalacia
Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
The researchers are trying to evaluate a newer imaging technique (Ga-DOTATATE PET/CT) to see if it is more sensitive to localize the source of the hormone, which has caused the low phosphate levels.
- Trial name
- NCT03736564
- Testing
- 68Ga-DOTATATE PET/CT
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Weight Loss, Obesity
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying.
- Trial name
- NCT00856609
- Testing
- Byetta (exenatide), Weight loss, Metabolic Chamber
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic Macular Edema
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema
The objective of this study is to investigate the safety and efficacy of minocycline as a microglia inhibitor in individuals with diabetic macular edema (DME).
- Trial name
- NCT01120899
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Type 2 Diabetes
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Trial name
- NCT01882907
- Testing
- vildagliptin, Pioglitazone
- Where
- 15 sites in South Korea
- Volunteers
- 287 people
- Sponsor
- Pusan National University Hospital
Pompe Disease
Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease
In this study the study team proposes to investigate the efficacy of albuterol on motor function of individuals with Late Onset Pompe Disease (LOPD) who are receiving enzyme replacement therapy, given albuterol was well-tolerated…
- Trial name
- NCT01885936
- Testing
- Albuterol
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Primary Objective: To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate…
- Trial name
- SOTA-GLIM (NCT03332771)
- Testing
- Sotagliflozin (SAR439954), Glimepiride, Metformin
- Where
- 142 sites in United States, Bulgaria and 2 more
- Volunteers
- 954 people
- Sponsor
- Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vitamin A Deficiency, Maternal Mortality
Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three…
- Conditions
- Vitamin A Deficiency, Maternal Mortality, Infant Mortality
- Trial name
- NCT00198822
- Testing
- Vitamin A or Beta-Carotene Supplements
- Where
- 3 sites in United States, Bangladesh
- Volunteers
- 59,666 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Gaucher Disease, Type 1
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular…
- Trial name
- NCT00553631
- Testing
- velaglucerase alfa, imiglucerase
- Where
- 11 sites in United States, Argentina and 7 more
- Volunteers
- 34 people
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.